Editas Medicine, Inc., a leading gene editing company developing transformative treatments for serious diseases, today announced its financial results for the first quarter of 2025 and provided key business updates.

According to Gilmore O’Neill, President and Chief Executive Officer of Editas Medicine, the company made significant progress during the first quarter in advancing its mission to lead the field of in vivo gene editing. He highlighted that recent scientific advancements have reinforced the company's confidence in the near-term potential of CRISPR-based in vivo gene editing therapies. Dr. O’Neill expressed pride in the team’s achievements in driving forward Editas’ in vivo programs, which hold promise for unlocking new therapeutic opportunities. He also conveyed optimism about the company’s continued progress toward clinical application.

Dr. O’Neill also announced the appointment of Amy Parison as Chief Financial Officer. Parison, who joined Editas in 2022 as Head of Finance, has demonstrated strong financial expertise, accounting proficiency, and leadership, making her a natural choice for the role.

Recent Achievements and Outlook
Upcoming Data Presentations
Editas Medicine is scheduled to present multiple sets of preclinical data supporting its in vivo gene editing programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13–17. Highlights include:

In vivo delivery of HBG1/2 promoter editing cargo to HSCs of humanized mice and non-human primates via lipid nanoparticles (LNPs)

CRISPR editing of genetic regulatory regions in vivo resulting in functional upregulation of target proteins and reduction in disease biomarkers in mice

Development of enhanced LNP-targeting ligands for improved hematopoietic stem cell editing

Use of chemically modified AsCas12a guide RNAs for improved LNP-delivered gene editing potency

In vivo gene editing and biomarker reduction across multiple liver targets in non-human primates using AsCas12a mRNA and guide RNAs delivered via LNPs

The company will also participate in TIDES USA 2025: Oligonucleotide & Peptide Therapeutics from May 19–22, presenting additional preclinical data and engaging in panel discussions.

Hematopoietic Stem Cells (HSCs)
At the ASGCT conference on May 14, Editas will present in vivo preclinical data from humanized mouse and non-human primate studies. These studies demonstrate the delivery of HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and/or HSCs in the bone marrow using targeted lipid nanoparticles (tLNPs).

Liver Cells
On May 13 and again at the TIDES conference, Editas will present preclinical proof-of-concept data for an undisclosed liver target. The studies showcase in vivo CRISPR editing resulting in increased target protein expression and reduced disease-associated biomarkers in a mouse model. Additional results from the company’s first in vivo mouse and non-human primate studies show robust liver gene editing and biomarker reduction following intravenous administration of AsCas12a mRNA and chemically modified guide RNAs, delivered in partnership with Genevant.

Platform Enhancements and Other Tissues
Editas will also showcase data on optimizations in guide modifications and targeting moieties designed to enhance the potency and precision of in vivo gene editing. The company remains on track to identify and disclose one additional target cell type or tissue—beyond HSCs and liver—by the end of the year.

Other Corporate Highlights
Leadership Update
Amy Parison has been appointed as Chief Financial Officer. With over 18 years of experience in life sciences finance and operations, she has held increasingly senior roles at Editas, including Senior Vice President of Finance and Corporate Controller. She has played a key role in executing the company's equity financings, licensing, and royalty monetization transactions. Before joining Editas, she was Corporate Controller at Rubius Therapeutics, where she built core financial systems post-IPO, and held finance roles at Vertex Pharmaceuticals. Her career began at PricewaterhouseCoopers LLP.

Intellectual Property
In a significant legal development, the U.S. Court of Appeals for the Federal Circuit vacated the Patent Trial and Appeal Board’s (PTAB) prior ruling and remanded the matter for further review. The case concerns CRISPR/Cas9 editing patents in human cells involving the University of California, the University of Vienna, Emmanuelle Charpentier, and the Broad Institute. Editas continues to express confidence in its intellectual property position and the strength of the Broad patents.

First Quarter 2025 Financial Results
As of March 31, 2025, Editas Medicine reported cash, cash equivalents, and marketable securities of $221.0 million, compared to $269.9 million as of December 31, 2024. The company expects these funds, along with retained payments from its license agreement with Vertex Pharmaceuticals, will support operations into the second quarter of 2027.

Key financial highlights for Q1 2025 include:

Net loss attributable to common stockholders was $76.1 million, or $0.92 per share, compared to $62.0 million, or $0.76 per share, for the same period in 2024.

Collaboration and R&D revenues rose to $4.7 million, up from $1.1 million in Q1 2024, driven by the recognition of deferred revenue from a concluded collaboration.

Research and development expenses decreased to $26.6 million from $48.8 million year-over-year, primarily due to the termination of the reni-cel program in December 2024.

General and administrative expenses fell to $13.4 million from $19.3 million in Q1 2024, largely due to reduced stock-based compensation costs.

Restructuring and impairment charges totaled $40.9 million, attributed to the discontinuation of the reni-cel program, associated workforce reductions, asset impairments, and adjusted depreciation timelines for impacted assets.

Source: https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2025-results-and